Halozyme Therapeutics, Inc. (HALO)
Last Price$61.4(0.0%)
Market Cap$7,773.1M
HALO Rating
HALO Quality rating performance
HALO Intrinsic Value
Key Highlights:
As of Mar 11, 2025 HALO Relative Value is $44.5, which is overvalued by 27.6%, compared to current share price of $61.4.
As of Mar 11, 2025 HALO DCF Value is $66.4, which is undervalued by 8.1%, compared to current share price of $61.4.
HALO Share Price History
1W 5.7%
1M 7.2%
6M 3.4%
YTD 64.3%
1Y 49.1%
3Y 76.9%
5Y 237.2%
10Y 298.6%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
HALO Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$7,773.1M
$8,682.9M
$1,015.3M
$468.4M
Shares Outstanding
127M
Employees
350
Growth (CAGR)
39.0%
N/A
17.2%
44.57%
Profitability
80.8%
54.3%
43.7%
47.2%
46.1%
105.5%
Intrinsic Value
$55.1 (10.3% overvalued)
$65.7
$44.5
$135.7
$154.8
74.0%
Return on Capital
Financial Health
$909.7M
1.9x
30.5x
413.9%
Dividends
Earnings
Aug 04, 2025
BEAT by 4.1%
BEAT by 7.1%
29.9%
8 Beat & 2 Miss
HALO Stock Financials
HALO Income Statement Metrics
Annual
Quarterly
LTM
HALO Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$479.1M +23.3% YoY
Capital Expenditure (CAPEX)
($10.7M) -30.1% YoY
Free Cash Flow (FCF)
$468.4M +25.5% YoY
HALO Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$1,015.3M 22.4% YoY
Cost of revenue
$159.4M (17.1%) YoY
Pre-tax income
$557.1M 59.9% YoY
54.9% margin
HALO Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$2,063.5M
Current assets ($1,085.3M, 52.6% of total)
$596.1M (28.9%)
$308.5M (14.9%)
Other current assets
$180.8M (8.8%)
Non-current assets ($978.1M, 47.4% of total)
$0.0 (0.0%)
$75.0M (3.6%)
$401.8M (19.5%)
Other non-current assets
$501.3M (24.3%)
Financial position
$909.7M
Cash & Short-term
Investments
Total Debt
HALO Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
HALO Earnings Surprises
Crunching data... Almost there!
HALO Dividends
HALO Dividend Yield
Crunching data... Almost there!
HALO Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with HALO
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$7,773.1M | 7.6 | $55.1 10.3% overvalued | 49.1% | $1,015.3M | $468.4M | 22.4% | 46.1% | 80.8% | 33.1% | 413.9% | |
$124.8B | 5.7 | $187.5 61.6% overvalued | 17.8% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$77.0B | 6.3 | $1,048.3 46.0% undervalued | (25.4%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$34.4B | 5.8 | $123.0 78.8% overvalued | 50.8% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$30.7B | 5.2 | $91.8 61.6% overvalued | 60.1% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$24.0B | 5.9 | $191.1 94.2% undervalued | 2.2% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.5B | 5.4 | $71.6 120.5% undervalued | 11.2% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$13.8B | 7.7 | $542.2 78.1% undervalued | 22.0% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.4B | 6.7 | $46.9 33.5% overvalued | (18.0%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$13.3B | 5.9 | $0.6 96.9% overvalued | 330.2% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$1,846.9M | 5.5 | $2,745.6 1,111.0% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
FAQ
What is Halozyme Therapeutics, Inc. (HALO) stock rating?
As of today, Halozyme Therapeutics, Inc. has a stock rating of 8 (out of 10), which is considered Great.
is Halozyme Therapeutics, Inc. (HALO) a good stock to buy?
As of today, Halozyme Therapeutics, Inc. has a Great stock rating, which is 10.3% overvalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 0.5%.